Carotid Intima Media Thickness (CIMT) in Epistaxis

Sponsor

University of Zurich (Other)

Overall Status

Completed

CT.gov ID

NCT03092973

Collaborator

(none)

Enrollment

Location

6.9

Actual Duration (Months)

11.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Epistaxis is a very frequent emergency among adults and often needs specialised treatment in an ENT-department. Among others, atherosclerosis is often named as a reason for an increased risk for Epistaxis. To evaluate whether or not this is the case, the investigators examined the carotid intima media thickness via ultrasound in patients who were treated in the ENT-department of the University Hospital of Zurich.

Condition or Disease	Intervention/Treatment	Phase
Epistaxis Atherosclerosis	Diagnostic Test: Ultrasound

Study Design

Study Type:

Observational

Actual Enrollment :

82 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Carotid Intima Media Thickness in Patients With Epistaxis: a Surrogate Marker for Generalised Atherosclerosis

Actual Study Start Date :

Dec 1, 2016

Actual Primary Completion Date :

Jun 30, 2017

Actual Study Completion Date :

Jun 30, 2017

Arms and Interventions

Arm	Intervention/Treatment
Epistaxis Group	Diagnostic Test: Ultrasound
Control Group	Diagnostic Test: Ultrasound

Arm

Intervention/Treatment

Epistaxis Group

Diagnostic Test: Ultrasound

Control Group

Diagnostic Test: Ultrasound

Outcome Measures

Primary Outcome Measures

Carotid Intima Media Thickness in Epistaxis vs. Controls [June 2017]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

active or very recently active anterior or posterior epistaxis
at least 18 years old

Exclusion Criteria:

posttraumatic or postoperative epistaxis

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University Hospital of Zurich	Zurich	ZH	Switzerland	8091

Sponsors and Collaborators

University of Zurich

Investigators

Principal Investigator: Michael Soyka, PD Dr. med., University of Zurich

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

University of Zurich

ClinicalTrials.gov Identifier:

NCT03092973

Other Study ID Numbers:

CIMT in Epistaxis

First Posted:

Mar 28, 2017

Last Update Posted:

Oct 30, 2017

Last Verified:

Oct 1, 2017

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Epistaxis

Atherosclerosis

Study Results

No Results Posted as of Oct 30, 2017